ArticleBreast cancer research and treatment2012
Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Article in Breast cancer research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Semiparametric model averaging prediction in nested case-control studies.Journal of applied statistics · 2025Article
- Trends in utilization of contralateral prophylactic mastectomy among different age, racial and ethnic groups.Gland surgery · 2023Article
- Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ.Breast cancer research and treatment · 2022Article
- Risk factors for contralateral breast cancer in postmenopausal breast cancer survivors in the NIH-AARP Diet and Health Study.Cancer causes & control : CCC · 2021Article
- Prevalence of Germline Pathogenic and Likely Pathogenic Variants in Patients With Second Breast Cancers.JNCI cancer spectrum · 2020Article
- A Prospective Study of Weight Gain in Women Diagnosed with Early-Stage Invasive Breast Cancer, Ductal CarcinomaJournal of women's health (2002) · 2020Article
- Problems to affect long-term survival for breast cancer patients: An observational study of subsequent lung/bronchus malignancies.Medicine · 2018Observational
- Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.Breast cancer research : BCR · 2017Article
- Mammographic breast density is associated with the development of contralateral breast cancer.Cancer · 2017Article
- A model for individualized risk prediction of contralateral breast cancer.Breast cancer research and treatment · 2017Article
- Identification of Biomarkers for Breast Cancer Using Databases.Journal of cancer prevention · 2016Review
- Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.Cancer medicine · 2016Article
- The Manchester guidelines for contralateral risk-reducing mastectomy.World journal of surgical oncology · 2015Article
- Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies.International journal of surgical oncology · 2015Review
- Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study.SpringerPlus · 2015Article
- Risk of contralateral second primary breast cancer according to hormone receptor status in Germany.Breast cancer research : BCR · 2014Article
- Bilateral breast cancers.Nature reviews. Clinical oncology · 2014Review
- Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy.PloS one · 2013Article
- Expression of HER2 in Breast Cancer Promotes a Massive Reorganization of Gene Activity and Suggests a Role for Epigenetic Regulation.Journal of data mining in genomics & proteomics · 2012Article
- A Rare Case of Triple Positive Metachronous Breast Cancer.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Breast cancer survivors have a 60 % higher risk of developing a second primary asynchronous contralateral breast cancer (CBC) compared to women's risk of developing a first primary breast cancer (FBC). However, little is known about how expression of tumor markers in first breast cancers influences CBC risk. We conducted a population-based nested case-control study among women 20-74 years of age diagnosed with a first breast cancer between 1996 and 2008 in western Washington State to evaluate the association between their tumor's estrogen receptor (ER), progesterone receptor (PR) and HER2-neu (HER2) expression, and risk of CBC. The study included 482 cases diagnosed with both a FBC and a CBC and 1,506 control women diagnosed only once with breast cancer identified through our local Surveillance, Epidemiology and End Results (SEER) cancer registry. Compared to the women whose FBC was ER+/PR+, those with ER-/PR- first tumors had a 1.6-fold (95 % confidence interval (CI): 1.2-2.3) increased risk of developing a CBC. When evaluated by joint ER/PR/HER2 status, compared to women with ER+/HER2- first cancers, those with HER2-overexpressing (ER-/HER2+) and triple-negative disease (ER-/PR-/HER2-) had 2.0-fold (95 % CI: 1.1-3.8) and 1.4-fold (95 % CI: 0.9-2.3) elevated risks of developing CBC, respectively. Beyond the known higher risks of mortality among patients diagnosed with more aggressive BC subtypes, here, we observe that they may also have increased risks of developing CBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.